Rinkey Investments Invests $229,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Rinkey Investments acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 321 shares of the biopharmaceutical company’s stock, valued at approximately $229,000.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Capital International Investors boosted its position in shares of Regeneron Pharmaceuticals by 41.6% during the 4th quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company’s stock valued at $3,373,859,000 after purchasing an additional 1,390,534 shares in the last quarter. Geode Capital Management LLC raised its stake in Regeneron Pharmaceuticals by 6.8% during the 4th quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company’s stock valued at $1,726,940,000 after purchasing an additional 155,369 shares during the period. Dodge & Cox grew its stake in Regeneron Pharmaceuticals by 0.4% during the 4th quarter. Dodge & Cox now owns 2,321,316 shares of the biopharmaceutical company’s stock valued at $1,653,543,000 after acquiring an additional 9,381 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in Regeneron Pharmaceuticals by 63.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company’s stock worth $1,485,527,000 after purchasing an additional 810,144 shares during the period. Finally, Franklin Resources Inc. lifted its position in Regeneron Pharmaceuticals by 7.9% during the 4th quarter. Franklin Resources Inc. now owns 2,045,210 shares of the biopharmaceutical company’s stock worth $1,456,864,000 after acquiring an additional 149,124 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $602.64 on Friday. The business has a 50 day moving average price of $637.38 and a 200 day moving average price of $725.82. The stock has a market cap of $65.88 billion, a price-to-earnings ratio of 15.74, a PEG ratio of 2.34 and a beta of 0.44. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $525.99 and a fifty-two week high of $1,211.20. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same period in the previous year, the firm posted $11.86 EPS. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. Equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were issued a $0.88 dividend. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.58%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 2.30%.

Analyst Ratings Changes

A number of equities analysts have recently commented on REGN shares. UBS Group downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $1,130.00 to $738.00 in a report on Thursday, January 16th. JPMorgan Chase & Co. dropped their price objective on shares of Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an “overweight” rating on the stock in a report on Monday, March 31st. Leerink Partnrs upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 5th. Bernstein Bank decreased their price objective on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. Finally, The Goldman Sachs Group lowered their price target on shares of Regeneron Pharmaceuticals from $1,019.00 to $917.00 and set a “buy” rating on the stock in a report on Monday, April 14th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, nineteen have given a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $945.32.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.